Data Bridge Market Research analyses that the pelvic cellulitis treatment market was valued at USD 378.91 million in 2021 and is expected to reach USD 530.65 million by 2029, registering a CAGR of 4.30% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Get a Sample PDF of the report – https://www.databridgemarketresearch.com/request-a-sample/?dbmr=glo...

In recent years, the pelvic cellulitis treatment market is anticipated to grow rapidly during the forecast period. Although the majority of patients arrive with abdominal symptoms or sepsis symptoms, intra-abdominal abscesses have a wide range of clinical presentations. Consistent stomach pain/tenderness, distention, mass, or ileus are all possible symptoms. Also prevalent are nausea, anorexia, and weight loss. Pelvic cellulitis are inflammatory, fluid-filled lumps that can develop in the female pelvic. Bacteria infiltrate the upper vaginal canal, causing abscesses. The bacteria usually comes from a different genital tract illness, such as pelvic inflammatory disease (PID), or germs from the lower genital tract that have made their way up through the cervix. Pelvic cellulitis in males are extremely uncommon, and when they do occur, they usually grow above the prostate. They are more common in women. All these factor led to the high demand of pelvic cellulitis treatment in the market.

Browse the complete table of contents at – https://www.databridgemarketresearch.com/toc/?dbmr=global-pelvic-ce...

Some of the major players operating in the pelvic cellulitis treatment market are:

Allergan (Ireland)

Merck & Co., Inc. (US)

Sumitomo Corporation (Japan)

Pfizer Inc. (US)

GlaxoSmithKline plc (UK)

Melinta Therapeutics LLC (US)

Basilea Pharmaceutica Ltd. (Switzerland)

Tetraphase Pharmaceuticals (US)

Paratek Pharmaceuticals, Inc. (US)

Nabriva Therapeutics plc (Ireland)

Spero Therapeutics (US)

Abbott (US)

F. Hoffmann-La Roche Ltd. (Switzerland)

Mylan N.V. (US)

Teva Pharmaceutical Industries Ltd.(Jerusalem)

Sanofi (France)

Novartis AG (Switzerland)

Sun Pharmaceutical Industries Ltd. (Mumbai)

Aurobindo Pharma (Hyderabad)

Lupin (Mumbai)

SHIONOGI & Co., Ltd. (Japan)

AbbVie Inc. (US)

Cumberland Pharmaceuticals Inc. (US)

Otsuka America Pharmaceutical, Inc. (US)

Eli Lilly and Company (US)

Market Definition

Pelvic cellulitis is commonly known as pelvic abscess. The most common causes of pelvic cellulitis include acute appendicitis, gynaecological diseases, and surgeries. It can also happen as a side effect of Crohn’s illness, diverticulitis, or abdominal surgery. An abscess is a collection of infected pus or fluid that is enclosed by inflammatory tissue. A pelvic abscess can grow fairly large before becoming ill or showing visible symptoms, making it easy to detect. The abscess is usually treated with antibiotics as well as draining the abscess. Antibiotics alone can be beneficial in the early stages of a minor abscess.

To Gain More Insights into the Market Analysis, Browse Summary of the Research Report@ https://www.databridgemarketresearch.com/reports/global-pelvic-cell...

COVID-19 Impact on Pelvic Cellulitis Treatment Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery, while prioritizing COVID-19-related treatments, healthcare systems around the world have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, and inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of pelvic cellulitis treatment in recent months.

Recent Development

In July 2020, Endo International plc had announced the launch of Qwo (collagenase clostridium histolyticum-aaes) with U.S. Food and Drug Administration (FDA) approval. QWO is a type of prescription drug that is used for the treatment of moderate to severe cellulite in the buttocks of adult women.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact Us:-

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email us:[email protected]